Current View on Drug-Resistant Tuberculosis: Diagnosis and Treatment

Call for Papers

Drug-resistant TB (DR-TB) can occur when the drugs used to treat TB are misused or mismanaged. Generally five terms can describe the variable forms of drug-resistant tuberculosis: (1) monoresistant: resistant to only one antituberculosis drug, (2) multidrug-resistant (MDR): resistant to at least isoniazid (INH) and rifampin (RIF), (3) polyresistant: resistant to more than one antituberculosis drug, but not the combination of INH and RIF, (4) extensively drug-resistant (XDR): resistant to at least INH and RIF, any fluoroquinolone, and at least one of three injectable second-line drugs (amikacin, kanamycin, or capreomycin), and (5) totally drug-resistant (TDR): resistant to all the first- and second-line TB drugs.

The problem of drug-resistant TB is growing throughout the world. It not only devastates the individuals and their families, but also imposes enormous burdens on overextended public health systems that lack the resources needed to contain it. Therefore, increased knowledge and understanding of drug-resistant tuberculosis disease could improve prevention strategies and could provide better treatment protocol for affected patients worldwide.

We invite investigators to contribute original research articles as well as review articles that will stimulate a greater understanding of drug resistant tuberculosis. Suggested areas of research include microbiologic and molecular diagnostic tools, drug susceptibility tests, human genetic susceptibility, prevalence and incidence studies, clinical presentations, and clinical trials for antibiotic therapy.

Potential topics include, but are not limited to:
  • Distribution scheme and epidemiologic characteristic of DR-TB
  • Recent developments in diagnosis of DR-TB
  • Advances in microbiology of DR-TB
  • Clinical evaluation and measuring treatment outcomes of DR-TB
  • Role of drug susceptibility testing in treatment of DR-TB
  • Application of new drugs for DR-TB

Authors can submit their manuscripts via the Manuscript Tracking System at Hindawi

Manuscript Due                Friday, 17 June 2016
First Round of Reviews     Friday, 9 September 2016
Publication Date               Friday, 4 November 2016


Lead Guest Editor

  • Ali A. Velayati, Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

Guest Editors
  • Biao Xu, Fudan University, Shanghai, China
  • Isabel Portugal, Universidade de Lisboa, Lisboa, Portugal
  • Rumina Hasan, Aga Khan University, Stadium Road, Karachi, Pakistan
  • Sven Hoffner, Public Health Agency of Sweden, Folkhälsomyndigheten, Sweden
     
Source : Hindawi Publishing Corporation      2016/1/20 08:38

خانه چاپ ارسال به دوستان نسخه متنی کوچک کردن متن بزرگ کردن متن دانلود خروجی پی دی اف خروجی میکروسافت ورد
0/10 (تعداد آرا 0 نفر )
Copyright © 2011 AASM. All Rights Reserved.